This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Social Bookmarking   What's this?

Samuel Dagogo-Jack, MD, FRCP; Julio V. Santiago, MD

Arch Intern Med. 1997;157(16):1802-1817.

Abstract
At least 90% of the 12 to 15 million persons with diabetes mellitus in the United States, half of whose condition remains undiagnosed, have type 2 diabetes. Type 2 diabetes is preceded by a long period of impaired glucose tolerance, a reversible metabolic state associated with increased prevalence of macrovascular complications. Thus, at the time of diagnosis, long-term complications have developed in almost one fourth of patients. Susceptibility to type 2 diabetes requires genetic (most likely polygenic) and acquired factors, and its pathogenesis involves an interplay of progressive insulin resistance and beta-cell failure. The ideal treatment of type 2 diabetes should reverse insulin resistance and beta-cell dysfunction in most treated patients and prevent, delay, or reverse long-term complications. Current strategies are aimed at amelioration of insulin resistance (diet, exercise, weight loss, and metformin and troglitazone therapy), augmentation of insulin supply (sulfonylurea and insulin therapy), or limitation of postprandial hyperglycemia (acarbose therapy). Future therapies probably will target (1) insulin resistance, using a multifaceted approach; (2) hepatic glucose production, using gluconeogenesis inhibitors; (3) excess nonesterified fatty acid production, using lipolysis inhibitors; and (4) fat oxidation, using carnitine palmitoyltransferase I and II inhibitors. Attempts also could be made to stimulate energy expenditure and increase nonoxidative glucose disposal by means of β3-adrenoceptor agonists. One promising strategy is an attack on multiple pathophysiological processes by combining antidiabetic agents with disparate mechanisms of action. Thus, we now have unprecedented resources for drug therapy for diabetes, with great opportunity for innovative combinations. It is hoped that these expanded choices will provide the tools necessary for a more efficient management of type 2 diabetes and prevention of its long-term complications.

Arch Intern Med. 1997;157:1802-1817

Author Affiliations
From the Division of Endocrinology, Diabetes, and Metabolism, Departments of Medicine (Drs Dagogo-Jack and Santiago) and Pediatrics (Dr Santiago), Washington University School of Medicine, St Louis, Mo.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Sulfonylureas and Ischemic Heart Disease
Robert Matz and Samuel Dagogo-Jack
Arch Intern Med. 1998;158(4):411-412.
EXTRACT | FULL TEXT  

Troglitazone: Monotherapy Indication
Donna M. Lisi and Samuel Dagogo-Jack
Arch Intern Med. 1998;158(4):412.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Genomes, Transcriptomes, and Proteomes: Molecular Medicine and Its Impact on Medical Practice
Gerling et al.
Arch Intern Med 2003;163:190-198.
ABSTRACT | FULL TEXT  

Inhibition of Kv2.1 Voltage-dependent K+ Channels in Pancreatic beta -Cells Enhances Glucose-dependent Insulin Secretion
MacDonald et al.
J. Biol. Chem. 2002;277:44938-44945.
ABSTRACT | FULL TEXT  

Members of the Kv1 and Kv2 Voltage-Dependent K+ Channel Families Regulate Insulin Secretion
MacDonald et al.
Mol. Endocrinol. 2001;15:1423-1435.
ABSTRACT | FULL TEXT  

Idiopathic Type 1 Diabetes in Dallas, Texas: A 5-year experience
Piñero-Piloña et al.
Diabetes Care 2001;24:1014-1018.
ABSTRACT | FULL TEXT  

Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease
Psaty et al.
JAMA 1999;282:786-790.
FULL TEXT  

Effects of Metformin in Patients with Poorly Controlled, Insulin-Treated Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial
Aviles-Santa et al.
ANN INTERN MED 1999;131:182-188.
ABSTRACT | FULL TEXT  

Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment
Mahler and Adler
J. Clin. Endocrinol. Metab. 1999;84:1165-1171.
FULL TEXT  

Treating Type 2 Diabetes with Respect
Nathan
ANN INTERN MED 1999;130:440-441.
FULL TEXT  

Cost of Troglitazone Therapy
Bachman and Dagogo-Jack
Arch Intern Med 1998;158:1038-1038.
FULL TEXT  

Troglitazone: Monotherapy Indication
Lisi and Dagogo-Jack
Arch Intern Med 1998;158:412-412.
FULL TEXT  

Sulfonylureas and Ischemic Heart Disease
Matz and Dagogo-Jack
Arch Intern Med 1998;158:411-412.
FULL TEXT